Selecting an anti-malarial clinical candidate from two potent dihydroisoquinolones

by Yizhe Chen, Fangyi Zhu, Jared Hammill, Gloria Holbrook, Lei Yang, Burgess Freeman, Karen L. White, David M. Shackleford, Kathleen G. O’Loughlin, Susan A. Charman, Jon C. Mirsalis, R. Kiplin Guy
Published 2021-02-01

The Anti-Inflammatory Drug Aspirin Does Not Protect Against Chemotherapy-Induced Memory Impairment by Paclitaxel in Mice

by Aeson Chang, Ni-Chun Chung, Adam J. Lawther, Alexandra I. Ziegler, David M. Shackleford, Erica K. Sloan, Erica K. Sloan, Adam K. Walker, Adam K. Walker, Adam K. Walker, Adam K. Walker
Published 2020-12-01

Effects of backbone cyclization on the pharmacokinetics and drug efficiency of the orally active analgesic conotoxin cVc1.1

by Aaron G. Poth, Francis C.K. Chiu, Sofie Stalmans, Brett R. Hamilton, Yen-Hua Huang, David M. Shackleford, Rahul Patil, Thao T. Le, Meng-Wei Kan, Thomas Durek, Evelien Wynendaele, Bart De Spiegeleer, Andrew K. Powell, Deon J. Venter, Richard J. Clark, Susan A. Charman, David J. Craik
Published 2021-06-01

An in vitro toolbox to accelerate anti-malarial drug discovery and development

by Susan A. Charman, Alice Andreu, Helena Barker, Scott Blundell, Anna Campbell, Michael Campbell, Gong Chen, Francis C. K. Chiu, Elly Crighton, Kasiram Katneni, Julia Morizzi, Rahul Patil, Thao Pham, Eileen Ryan, Jessica Saunders, David M. Shackleford, Karen L. White, Lisa Almond, Maurice Dickins, Dennis A. Smith, Joerg J. Moehrle, Jeremy N. Burrows, Nada Abla
Published 2020-01-01

The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson’s disease

by David I. Finkelstein, Jessica L. Billings, Paul A. Adlard, Scott Ayton, Amelia Sedjahtera, Colin L. Masters, Simon Wilkins, David M. Shackleford, Susan A. Charman, Wojciech Bal, Izabela A Zawisza, Ewa Kurowska, Andrew L. Gundlach, Sheri Ma, Ashley I. Bush, Dominic J. Hare, Philip A. Doble, Simon Crawford, Elisabeth CL. Gautier, Jack Parsons, Penny Huggins, Kevin J. Barnham, Robert A. Cherny
Published 2017-06-01

Correction to: The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson’s disease

by David I. Finkelstein, Jessica L. Billings, Paul A. Adlard, Scott Ayton, Amelia Sedjahtera, Colin L. Masters, Simon Wilkins, David M. Shackleford, Susan A. Charman, Wojciech Bal, Izabela A. Zawisza, Ewa Kurowska, Andrew L. Gundlach, Sheri Ma, Ashley I. Bush, Dominic J. Hare, Philip A. Doble, Simon Crawford, Elisabeth C. L. Gautier, Jack Parsons, Penny Huggins, Kevin J. Barnham, Robert A. Cherny
Published 2021-09-01

A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance

by Paul M. O’Neill, Richard K. Amewu, Susan A. Charman, Sunil Sabbani, Nina F. Gnädig, Judith Straimer, David A. Fidock, Emma R. Shore, Natalie L. Roberts, Michael H.-L. Wong, W. David Hong, Chandrakala Pidathala, Chris Riley, Ben Murphy, Ghaith Aljayyoussi, Francisco Javier Gamo, Laura Sanz, Janneth Rodrigues, Carolina Gonzalez Cortes, Esperanza Herreros, Iñigo Angulo-Barturén, María Belén Jiménez-Díaz, Santiago Ferrer Bazaga, María Santos Martínez-Martínez, Brice Campo, Raman Sharma, Eileen Ryan, David M. Shackleford, Simon Campbell, Dennis A. Smith, Grennady Wirjanata, Rintis Noviyanti, Ric N. Price, Jutta Marfurt, Michael J. Palmer, Ian M. Copple, Amy E. Mercer, Andrea Ruecker, Michael J. Delves, Robert E. Sinden, Peter Siegl, Jill Davies, Rosemary Rochford, Clemens H. M. Kocken, Anne-Marie Zeeman, Gemma L. Nixon, Giancarlo A. Biagini, Stephen A. Ward
Published 2017-05-01